Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

Marwan Fakih,Kanwal Pratap Singh Raghav,David Z. Chang,Johanna C. Bendell,Timothy S. Larson,Allen Lee Cohn,Timothy K. Huyck,David O. Cosgrove,Joseph A. Fiorillo,Lawrence E. Garbo,Shruthi Ravimohan,Von Potter,David DAdamo,Neelesh Sharma,Ying A. Wang,Sabine Coppieters,Matthias Herpers,Carolina Soares Viana de Oliveira,Andrew Scott Paulson

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

2021

Marwan Fakih
Kanwal Pratap Singh Raghav
David Z. Chang
Johanna C. Bendell
Timothy S. Larson
Allen Lee Cohn
Timothy K. Huyck
David O. Cosgrove
Joseph A. Fiorillo
Lawrence E. Garbo
Shruthi Ravimohan
Von Potter
David DAdamo
Neelesh Sharma
Ying A. Wang
Sabine Coppieters
Matthias Herpers
Carolina Soares Viana de Oliveira
Andrew Scott Paulson

3560Background: The role of immunotherapy in the treatment of pMMR/MSS metastatic CRC is not established. A Japanese phase 1b trial in this setting showed the combination of regorafenib (multikinas...

Keywords:

Medicine
Internal medicine
DNA mismatch repair
Nivolumab
Oncology
in patient
Colorectal cancer
Phases of clinical research
Regorafenib
Microsatellite Stable
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations